search
Back to results

Non-opioid Analgesic Combination With Morphine for Postoperative Analgesia. (OCTOPUS)

Primary Purpose

Post Operative Analgesia

Status
Terminated
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
Paracetamol
Nefopam
Ketoprofen
Morphine
Sponsored by
Rennes University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Post Operative Analgesia focused on measuring Post operative analgesia ;, Paracetamol ;, Ketoprofen ;, Nefopam ;, Morphine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adults older than 18 years
  • Receiving scheduled surgery requiring the use of a PCA to treat postoperative pain
  • Patients with a written informed consent
  • Patients with a written informed consent for the sub-study on hyperalgesia (patients in the centers concerned)
  • Affiliate to a social security system

Exclusion Criteria:

  • Allergy to morphine, paracetamol, nefopam or ketoprofen or to any of their excipients
  • Absorption of morphine and / or NOA within 24 hours before surgery
  • Absorption of methadone within 48 hours before surgery
  • History of epilepsy
  • Renal insufficiency (creatinin clearance <30 ml / min MDRD)
  • Hepatic insufficiency
  • Severe respiratory insufficiency
  • Pregnancy or breastfeeding women
  • History of seizures
  • Symptomatic urethroprostatic disorders
  • Angle-closure glaucoma
  • Gastrointestinal, cerebrovascular or other evolving bleedings
  • Active peptic ulcer or active gastritis
  • Severe heart failure
  • History of asthma triggered by taking ketoprofen or similar substances
  • Disable adult person under guardianship
  • Use of nitrous oxide during anesthesia protocol

Sites / Locations

  • Karine Nouette-Gaulain
  • Marcel Chauvin
  • Hawa Keita-Meyer
  • Dominique Fletcher
  • Pierre Albaladejo
  • Frédéric Aubrun
  • Xavier Capdevila
  • Hervé Bouaziz
  • Karim Asehnoune
  • Marc Raucoules
  • Jacques Ripart
  • Anissa Belbachir
  • Emmanuel Marret
  • Jean-Xavier Mazoit
  • Marc Beaussier
  • Sébastien Bloc
  • Jean-Marc Malinovsky
  • Marc Gentili
  • Vincent Minville

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Control group C: Placebo

Group P: Paracetamol

Group N: Nefopam

Group K: Ketoprofen

Group PN: paracetamol and nefopam

Group PK: paracetamol and ketoprofen

Group NK: nefopam and ketoprofen

Group PNK: paracetamol, nefopam and ketoprofen

Arm Description

All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.

All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.

All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.

All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.

All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.

All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.

All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.

All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.

Outcomes

Primary Outcome Measures

Morphine consumption (mg), accumulated over 24 hours, measured by patient controlled analgesia (PCA).

Secondary Outcome Measures

Morphine consumption (mg) measured by patient controlled analgesia (PCA).
Incidence of side effects associated with morphine: nausea, vomiting, sedation, urinary retention, pruritus.
Area of hyperalgesia measured using a von Frey filament expressed in cm2, 48 hours after surgery (sub-study in 3 centers).
Incidence of chronic pain assessed by a telephone questionnaire 3 months after surgery (sub-study in 3 centers).
Global satisfaction (measured after treatment)

Full Information

First Posted
June 18, 2013
Last Updated
February 2, 2018
Sponsor
Rennes University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01882530
Brief Title
Non-opioid Analgesic Combination With Morphine for Postoperative Analgesia.
Acronym
OCTOPUS
Official Title
Prospective, Controlled Versus Placebo, Randomized, Double-blind Study, Evaluating the Value of Non-opioid Analgesic Combination (Based on Paracetamol, Nefopam, Ketoprofen) for Postoperative Analgesia.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Terminated
Why Stopped
Practice on postoperative pain management changed
Study Start Date
July 23, 2013 (Actual)
Primary Completion Date
January 16, 2016 (Actual)
Study Completion Date
January 16, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rennes University Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The combination of different analgesic drugs and/or analgesia techniques is part of the standard management of postoperative analgesia. The analysis of the literature reveals a lack of comparison of the associations of non-opioid analgesic (NOA) with morphine for postoperative analgesia. The objectives of this study are : comparing the morphine sparing effect of different combination of 3 NOA (paracetamol, nefopam, ketoprofen) for postoperative analgesia. determining whether the morphine-sparing effect is associated with or without a reduction in the incidence of morphine side effects. evaluating the effects of NOA on postoperative hyperalgesia.
Detailed Description
Since the description of the concept of balanced analgesia in the early 90's, the combination of different analgesic drugs and/or analgesia techniques is part of the standard management of postoperative analgesia. A recent survey conducted in France by Fletcher et al. showed that patients often received one or more NOA associated with an opioid. The benefit and risk of the use of opioids associated with NOA were recently reassessed as part of a formal recommendation of experts and detailed in a recent review. The analysis of the literature reveals a lack of comparison of the combinations of NOA with morphine for postoperative analgesia. For example, paracetamol and morphine in combination does not always allow a significant morphine-sparing effect compared with morphine alone and does not reduce the incidence of morphine side effects. A number of definitive answers has therefore yet to be found: Does NOA -morphine association allow an effective morphine-sparing effect? Is there an interest in prescribing several NOAs in association? If yes, what are the most interesting combinations in terms of morphine-sparing effect and safety? Another question concerns the effects of NOA on postoperative hyperalgesia. This hyperalgesia, which results from surgery-related inflammation, is increased by consumption of morphine and not only contributes to the overall experience of postoperative pain but also to the chronicisation of postoperative pain. Since in clinical practice, hyperalgesia can be measured using specific tools (Von Frey filament type), our study will evaluate the anti-hyperalgesic effects of NOA on a subgroup of patients enrolled in the centers used to evaluate nociceptive thresholds. The objectives of this study are : comparing the morphine sparing effect of different combination of 3 NOA (paracetamol, nefopam, ketoprofen) for postoperative analgesia. determining whether the morphine-sparing effect is associated with or without a reduction in the incidence of morphine side effects. evaluating the effects of NOA on postoperative hyperalgesia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post Operative Analgesia
Keywords
Post operative analgesia ;, Paracetamol ;, Ketoprofen ;, Nefopam ;, Morphine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
223 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control group C: Placebo
Arm Type
Placebo Comparator
Arm Description
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Arm Title
Group P: Paracetamol
Arm Type
Experimental
Arm Description
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Arm Title
Group N: Nefopam
Arm Type
Experimental
Arm Description
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Arm Title
Group K: Ketoprofen
Arm Type
Experimental
Arm Description
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Arm Title
Group PN: paracetamol and nefopam
Arm Type
Experimental
Arm Description
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Arm Title
Group PK: paracetamol and ketoprofen
Arm Type
Experimental
Arm Description
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Arm Title
Group NK: nefopam and ketoprofen
Arm Type
Experimental
Arm Description
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Arm Title
Group PNK: paracetamol, nefopam and ketoprofen
Arm Type
Experimental
Arm Description
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
Intervention Type
Drug
Intervention Name(s)
Paracetamol
Intervention Type
Drug
Intervention Name(s)
Nefopam
Intervention Type
Drug
Intervention Name(s)
Ketoprofen
Intervention Type
Drug
Intervention Name(s)
Morphine
Other Intervention Name(s)
All patients will receive morphine postoperatively (titration, then PCA).
Primary Outcome Measure Information:
Title
Morphine consumption (mg), accumulated over 24 hours, measured by patient controlled analgesia (PCA).
Time Frame
Day 1
Secondary Outcome Measure Information:
Title
Morphine consumption (mg) measured by patient controlled analgesia (PCA).
Time Frame
Day 2, day 3
Title
Incidence of side effects associated with morphine: nausea, vomiting, sedation, urinary retention, pruritus.
Time Frame
Day 3
Title
Area of hyperalgesia measured using a von Frey filament expressed in cm2, 48 hours after surgery (sub-study in 3 centers).
Time Frame
Day 2
Title
Incidence of chronic pain assessed by a telephone questionnaire 3 months after surgery (sub-study in 3 centers).
Time Frame
Month 3
Title
Global satisfaction (measured after treatment)
Time Frame
Day 3

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults older than 18 years Receiving scheduled surgery requiring the use of a PCA to treat postoperative pain Patients with a written informed consent Patients with a written informed consent for the sub-study on hyperalgesia (patients in the centers concerned) Affiliate to a social security system Exclusion Criteria: Allergy to morphine, paracetamol, nefopam or ketoprofen or to any of their excipients Absorption of morphine and / or NOA within 24 hours before surgery Absorption of methadone within 48 hours before surgery History of epilepsy Renal insufficiency (creatinin clearance <30 ml / min MDRD) Hepatic insufficiency Severe respiratory insufficiency Pregnancy or breastfeeding women History of seizures Symptomatic urethroprostatic disorders Angle-closure glaucoma Gastrointestinal, cerebrovascular or other evolving bleedings Active peptic ulcer or active gastritis Severe heart failure History of asthma triggered by taking ketoprofen or similar substances Disable adult person under guardianship Use of nitrous oxide during anesthesia protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
ERIC BELLISSANT
Organizational Affiliation
Rennes University Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Karine Nouette-Gaulain
City
Bordeaux
Country
France
Facility Name
Marcel Chauvin
City
Boulogne
Country
France
Facility Name
Hawa Keita-Meyer
City
Colombes
Country
France
Facility Name
Dominique Fletcher
City
Garches
Country
France
Facility Name
Pierre Albaladejo
City
Grenoble
Country
France
Facility Name
Frédéric Aubrun
City
Lyon
Country
France
Facility Name
Xavier Capdevila
City
Montpellier
Country
France
Facility Name
Hervé Bouaziz
City
Nancy
Country
France
Facility Name
Karim Asehnoune
City
Nantes
Country
France
Facility Name
Marc Raucoules
City
Nice
Country
France
Facility Name
Jacques Ripart
City
Nîmes
Country
France
Facility Name
Anissa Belbachir
City
Paris
Country
France
Facility Name
Emmanuel Marret
City
Paris
Country
France
Facility Name
Jean-Xavier Mazoit
City
Paris
Country
France
Facility Name
Marc Beaussier
City
Paris
Country
France
Facility Name
Sébastien Bloc
City
Quincy sous Sénart
Country
France
Facility Name
Jean-Marc Malinovsky
City
Reims
Country
France
Facility Name
Marc Gentili
City
St Grégoire
Country
France
Facility Name
Vincent Minville
City
Toulouse
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
30915987
Citation
Beloeil H, Albaladejo P, Sion A, Durand M, Martinez V, Lasocki S, Futier E, Verzili D, Minville V, Fessenmeyer C, Belbachir A, Aubrun F, Renault A, Bellissant E; OCTOPUS group. Multicentre, prospective, double-blind, randomised controlled clinical trial comparing different non-opioid analgesic combinations with morphine for postoperative analgesia: the OCTOPUS study. Br J Anaesth. 2019 Jun;122(6):e98-e106. doi: 10.1016/j.bja.2018.10.058. Epub 2018 Dec 29.
Results Reference
derived

Learn more about this trial

Non-opioid Analgesic Combination With Morphine for Postoperative Analgesia.

We'll reach out to this number within 24 hrs